Back Login for AI Analysis

    ORKA (STOCKS)

    Oruka Therapeutics, Inc. Common Stock

    $62.000000
    +2.420000 (+4.06%)
    Prev close: $59.580000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Lawrence O. Klein
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $3,038.95M
    Employees
    28
    P/E (TTM)
    -26.48
    P/B (TTM)
    6.19
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Dec 2025)
    Revenues $0.00
    Nonoperating Income/Loss $16.62M
    Operating Expenses $122.05M
    Research and Development $100.64M
    Other Operating Expenses $21.41M
    Operating Income/Loss -$122.05M
    Income/Loss From Continuing Operations After Tax -$105.43M
    Income/Loss From Continuing Operations Before Tax -$105.43M
    Net Income/Loss -$105.43M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$105.43M
    Net Income/Loss Available To Common Stockholders, Basic -$105.43M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Assets $488.62M
    Current Assets $343.86M
    Noncurrent Assets $144.76M
    Fixed Assets $288.00K
    Other Non-current Assets $144.47M
    Liabilities $16.69M
    Current Liabilities $15.37M
    Noncurrent Liabilities $1.31M
    Equity $471.93M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $471.93M
    Liabilities And Equity $488.62M
    Net Cash Flow From Operating Activities -$88.21M
    Net Cash Flow From Operating Activities, Continuing -$88.21M
    Net Cash Flow From Investing Activities -$96.75M
    Net Cash Flow From Investing Activities, Continuing -$96.75M
    Net Cash Flow From Financing Activities $170.32M
    Net Cash Flow From Financing Activities, Continuing $170.32M
    Net Cash Flow -$14.64M
    Net Cash Flow, Continuing -$14.64M
    Comprehensive Income/Loss -$104.85M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$104.85M
    Other Comprehensive Income/Loss -$104.85M